Keros Therapeutics Inc (KROS) — Cash Flow-to-Debt Ratio
Keros Therapeutics Inc (KROS) has a Cash Flow-to-Debt Ratio of 0.08x as of September 2025, meaning its operating cash flow of $3.25 Million could theoretically repay 0% of its total liabilities ($39.20 Million) in one year. See KROS cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Keros Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2024)
Historical debt coverage capacity for Keros Therapeutics Inc across 7 annual periods. Also explore Keros Therapeutics Inc (KROS) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Keros Therapeutics Inc (2018–2024)
Year-by-year debt coverage analysis for Keros Therapeutics Inc. For market capitalisation and broader financial context, see KROS company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.63x | $-160.87 Million | $44.33 Million | ▼ -10.2% |
| 2023 | -3.29x | $-124.51 Million | $37.81 Million | ▼ -38.0% |
| 2022 | -2.39x | $-70.06 Million | $29.36 Million | ▲ +53.6% |
| 2021 | -5.15x | $-62.15 Million | $12.08 Million | ▼ -7.7% |
| 2020 | -4.78x | $-36.89 Million | $7.72 Million | ▼ -64.4% |
| 2019 | -2.91x | $-16.00 Million | $5.50 Million | ▼ -704.8% |
| 2018 | 0.48x | $7.04 Million | $14.65 Million | — |